Chemical Namevismodegib
Dosage FormCapsules (oral; 150mg)
Drug ClassInhibitors
CompanyGenentech Inc.
Approval Year2012


  • For the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Erivedge (vismodegib) Prescribing Information2012Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Vismodegib for treating basal cell carcinoma.2017NICE
Document TitleYearSource
Guidelines of care for the management of basal cell carcinoma.2018American Academy of Dermatology
Basal cell skin cancer, version 1.2016.2016Journal of the National Comprehensive Cancer Network